AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease • Potentially registrational trial is targeting enrollment of approximately 500 participants with pre-symptomatic AD • FDA Fast Track designation granted in ...
| Ticker |
Sentiment |
Impact |
|
ACIU
|
Neutral
|
30 %
|
|
JNJ
|
Neutral
|
30 %
|
